60 Degrees Pharmaceuticals Inc
SXTP
View Detailed Chart
0.689USD
-0.049-6.65%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.83MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-6.65%
5 Days
-18.83%
1 Month
-31.77%
6 Months
-70.68%
Year to Date
-89.32%
1 Year
-89.56%
View Detailed Chart
TradingKey Stock Score of 60 Degrees Pharmaceuticals Inc
Currency: USD Updated: 2025-12-24Key Insights
60 Degrees Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 110/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.40.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
60 Degrees Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.400
Target Price
+348.98%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
60 Degrees Pharmaceuticals Inc Highlights
StrengthsRisks
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 33.28% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 681.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 681.35K.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 451.55K shares, increasing 46.05% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 81.00 shares of this stock.
60 Degrees Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
60 Degrees Pharmaceuticals Inc Info
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Ticker SymbolSXTP
Company60 Degrees Pharmaceuticals Inc
CEODow (Geoffrey S)
Websitehttps://60degreespharma.com/
FAQs
What is the current price of 60 Degrees Pharmaceuticals Inc (SXTP)?
The current price of 60 Degrees Pharmaceuticals Inc (SXTP) is 0.689.
What is the symbol of 60 Degrees Pharmaceuticals Inc?
The ticker symbol of 60 Degrees Pharmaceuticals Inc is SXTP.
What is the 52-week high of 60 Degrees Pharmaceuticals Inc?
The 52-week high of 60 Degrees Pharmaceuticals Inc is 8.000.
What is the 52-week low of 60 Degrees Pharmaceuticals Inc?
The 52-week low of 60 Degrees Pharmaceuticals Inc is 0.720.
What is the market capitalization of 60 Degrees Pharmaceuticals Inc?
The market capitalization of 60 Degrees Pharmaceuticals Inc is 2.83M.
What is the net income of 60 Degrees Pharmaceuticals Inc?
The net income of 60 Degrees Pharmaceuticals Inc is -8.43M.
Is 60 Degrees Pharmaceuticals Inc (SXTP) currently rated as Buy, Hold, or Sell?
According to analysts, 60 Degrees Pharmaceuticals Inc (SXTP) has an overall rating of Buy, with a price target of 4.400.
What is the Earnings Per Share (EPS TTM) of 60 Degrees Pharmaceuticals Inc (SXTP)?
The Earnings Per Share (EPS TTM) of 60 Degrees Pharmaceuticals Inc (SXTP) is -73.901.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
